Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Intersect ENT, a leader in ENT medical technology, announced participation in the 39th Annual J.P. Morgan Healthcare Conference. Management, including CEO Tom West and CFO Randy Meier, will present on January 12, 2021, at 5:00 p.m. ET. A live webcast will be available on their website, with a replay following the event.

Intersect ENT specializes in steroid-releasing implants for targeted therapy and has expanded its product portfolio through the acquisition of Fiagon AG Medical Technologies, enhancing its market presence.

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39^th Annual J.P. Morgan Healthcare Conference. Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will present at 5:00 p.m. ET / 2:00 p.m. PT on Tuesday, January 12, 2021.

A live webcast of the presentation can be accessed by visiting the “Investor Relations” page of the Company’s website at www.intersectENT.com. A replay will be available on the Company’s website following the event.

About Intersect ENT

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings that complement the Company’s PROPEL^® and SINUVA^® sinus implants and extend its geographic reach.

For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL^® (mometasone furoate) sinus implants and SINUVA^® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.

Intersect ENT^®, PROPEL^® and SINUVA^® are registered trademarks of Intersect ENT, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006091/en/

FAQ

When is Intersect ENT's presentation at the J.P. Morgan Healthcare Conference?

Intersect ENT will present on January 12, 2021, at 5:00 p.m. ET.

Who from Intersect ENT will be speaking at the conference?

Tom West, the CEO, and Randy Meier, the CFO, will be presenting.

Where can I watch Intersect ENT's conference presentation?

The presentation can be accessed via the Investor Relations page on Intersect ENT's website.

What recent acquisition did Intersect ENT make?

In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies.

What products does Intersect ENT offer?

Intersect ENT specializes in steroid-releasing implants such as PROPEL® and SINUVA® for sinus treatment.